吡格列酮用于糖尿病患者的大血管二级预防。前瞻性吡格列酮大血管事件临床试验（PROactive研究） - Suppr

Suppr

超能文献

[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].

作者信息

Nitschmann S

出版信息

Internist (Berl). 2007 Jan;48(1):89-90; discussion 90-1. doi: 10.1007/s00108-006-1777-6.

DOI:10.1007/s00108-006-1777-6

PMID:17187243

Abstract

摘要

相似文献

[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].

Internist (Berl). 2007 Jan;48(1):89-90; discussion 90-1. doi: 10.1007/s00108-006-1777-6.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. doi: 10.1016/j.jacc.2006.12.048. Epub 2007 Apr 16.

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836.

[Prospective pioglitazone clinical trial in macrovascular events].

Nihon Rinsho. 2012 May;70 Suppl 3:301-8.

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

J Diabetes. 2010 Sep;2(3):212-20. doi: 10.1111/j.1753-0407.2010.00082.x.

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

Diabetes Care. 2004 Jul;27(7):1647-53. doi: 10.2337/diacare.27.7.1647.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9.

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Diabet Med. 2007 Sep;24(9):982-1002. doi: 10.1111/j.1464-5491.2007.02188.x. Epub 2007 Jun 25.

The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.

Curr Diab Rep. 2006 Feb;6(1):45-6. doi: 10.1007/s11892-006-0051-6.

Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.

Diabetes Obes Metab. 2016 Mar;18(3):266-73. doi: 10.1111/dom.12608. Epub 2016 Jan 8.

引用本文的文献

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Cost Eff Resour Alloc. 2009 May 5;7:9. doi: 10.1186/1478-7547-7-9.

本文引用的文献

PROactive study.

Lancet. 2006 Jan 7;367(9504):24-5; author reply 26-7. doi: 10.1016/S0140-6736(06)67913-0.

The PROactive study: some answers, many questions.

Lancet. 2005 Oct 8;366(9493):1241-2. doi: 10.1016/S0140-6736(05)67504-6.

Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

Diabetes Care. 2004 Mar;27(3):699-703. doi: 10.2337/diacare.27.3.699.

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

N Engl J Med. 1998 Jul 23;339(4):229-34. doi: 10.1056/NEJM199807233390404.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验